Nov 18, 2021 / NTS GMT
RenéC. Goehrum - BioSyent Inc. - Chairman, CEO & President
Hello, and welcome to the BioSyent Inc. Q3 and YTD 2021 results presentation for the 9 months ended September 30. My name is René Goehrum, and I'm the President and CEO of the company.
I'm going to start today's presentation with a look at our sales, EBITDA and net income after tax for the 3 months ended September 30 of '21.
As you can see, our sales were just below $6.7 million in the quarter. That was an increase of 16% versus the year ago, driven by our Canadian Pharmaceutical business, up 17% measured in dollars, and we did not ship to any International Pharmaceutical customers in the quarter. I've got some more comments on that in subsequent slides. And our Legacy Business was down 5% in the quarter.
Our EBITDA was just under $2.3 million, representing a 64% increase to the year ago, and our net profit of $1.72 million was up 80% to the year ago. It represented our 45th consecutive profitable quarter and our net margin after tax of 26% represented a high watermark in quite some period of time.
Q3 2021 Biosyent Inc Earnings Call Transcript
Nov 18, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers